JP Morgan 2024 – Jeff Smith
Editor-in-chief Jonah Comstock sat down with Jeff Smith, chief research officer at Precision BioSciences, on the side lines of the JP Morgan Healthcare Conference in San Francisco to discuss his work and broader biotech trends.
Precision Biosciences is a biotech looking to take in vivo gene editing beyond CRISPR-Cas9. Smith discusses ARCUS, Precision’s core gene editing technology, and how it differs from, and improves on, other approaches.
They also talk a little about the state of gene therapy in general and how recent approvals will help to smooth out the road for all stripes of gene tech companies. Smith also gets into the future of gene editing and how his company’s differentiated technology is well positioned as the technology moves beyond simple gene knockouts to more complex insert-and-replace editing.
Tune in for an interesting gene therapy explainer, and stay tuned for many more videos from JP Morgan 2024 over the next several weeks.
